Abstract
The purpose of this study was to investigate the effect of omega-3 poly unsaturated fatty-acids co-administered with the therapeutic dose of lornoxicam on liver of healthy rats. Twenty-eight adults male rats weighing 180-200g were used in this study and the animals were randomly divided into four groups of seven rats each. Group I: negative control/rats intraperitoneally injected with normal saline in a dose 5ml/kg/day; Group II: rats intraperitoneally injected with lornoxicam at dose 0.7 mg/kg/day; Group III: rats orally-administered omega-3 only at a dose 185mg/kg/day; Group IV: rats co-administered omega-3 (185mg/kg/day) orally and intra-peritoneal injection of lornoxicam (0.7 mg/kg/day). Duration of treatment was 14-day; and at day 15 of the study, the liver of each rat was excised for the preparation of tissue-homogenate to be utilized for the estimation of ALT, AST, TNF-alpha and IL-10. Omega-3 can reduce signs of inflammation through the reduction- of TNF-alpha level and elevation of IL-10 with a significant reduction in ALT enzyme activity level in rats' liver tissue homogenate. In conclusion, Omega-3 poly-unsaturated fatty-acids may have a protective effect against hepatocytes inflammation when co-administered with lornoxicam.
Highlights
The liver is the fundamental and major site of drugs-metabolism; and non-steroidal antiinflammatory drugs (NSAIDs) are the most widely utilized medications for pain-control and inflammation in several countries [1]
Authors reported that drug–drug interactions (DDIs) have been noticed when NSAIDs are co-administered with some common medications [9]; the safety profile of NSAIDs alone, and in combination with other medications and supplements needs to be assessed in healthy status
There was nonsignificant difference (P>0.05) in IL-10 level in Group II rats' liver tissue homogenate treated with therapeutic dose of lornoxicam (0.7mg/kg) compared to negative control rats (Group I)
Summary
The liver is the fundamental and major site of drugs-metabolism; and non-steroidal antiinflammatory drugs (NSAIDs) are the most widely utilized medications for pain-control and inflammation in several countries [1]. Lornoxicam is a potent NSAID with analgesic, antipyretic and anti-inflammatory effects that used to relieve the pain of postoperative in orthopaedic surgery [3] [4]. Lornoxicam caused adverse effects during its hepatic metabolism [5]. Omega-3 poly-unsaturated fatty-acid (PUFAs) including docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) is an essential oil for the development of fetal and health aging; it plays a role in anti-inflammatory process and cell membrane viscosity [6,7]. It has been reported that the intake of omega-3 PUFA may provide a protective impact against the most common adverse effects of NSAIDs such as cardiovascular and gastrointestinal [8]. Authors reported that drug–drug interactions (DDIs) have been noticed when NSAIDs are co-administered with some common medications [9]; the safety profile of NSAIDs alone, and in combination with other medications and supplements needs to be assessed in healthy status
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Iraqi Journal of Pharmaceutical Sciences ( P-ISSN: 1683 - 3597 , E-ISSN : 2521 - 3512)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
